自身免疫性风湿病患者大规模人群中第三剂同源灭活SARS-CoV-2疫苗后免疫原性增强
本研究纳入597例自身免疫性风湿病(ARD)患者和199例年龄性别匹配对照,均在接种两剂CoronaVac后6个月(D210)接种第三剂,并于D240评估抗SARS-CoV-2 S1/S2 IgG和中和抗体(NAb)。ARD患者抗S1/S2 IgG阳性率从D210的60%升至D240的93%(p<0.0001),NAb阳性率从38%升至81.4%(p<0.0001),对照亦呈相似升高。多因素分析显示高龄、血管炎、泼尼松≥5 mg/天、MMF和生物制剂与抗S1/S2 IgG阳性率降低相关,泼尼松≥5 mg/天、阿巴西普、贝利尤单抗和利妥昔单抗与NAb阳性率降低相关。
要点
- ARD患者第三剂CoronaVac后抗S1/S2 IgG阳性率由D210的60%升至D240的93%,NAb阳性率由38%升至81.4%。
- D210时COVID-19血清阴性的ARD患者D240抗S1/S2 IgG阳性率达80.5%,NAb阳性率达59.1%。
- 泼尼松≥5 mg/天、MMF、生物制剂、血管炎、高龄与抗S1/S2 IgG阳性率降低相关,MTX除外。
核心结论
- ARD患者对第三剂CoronaVac呈现稳健的免疫应答,即使接种前COVID-19血清阴性者亦如此。
- 常规两剂方案后降低免疫原性的药物(MTX除外)与第三剂后无应答相关。
研究设计与样本
- 研究纳入597例成人ARD患者和199例年龄性别匹配对照,两组年龄可比(p=0.943),均在接种两剂CoronaVac后6个月(D210)接种第三剂。
- 于D210和D240检测抗SARS-CoV-2 S1/S2 IgG和中和抗体(NAb);疾病控制稳定的患者在接种后暂停MMF 7天或MTX 2周剂量。
- 试验注册号NCT04754698。
主要发现
- ARD患者抗S1/S2 IgG阳性率从D210的60%升至D240的93%(p<0.0001),NAb阳性率从38%升至81.4%(p<0.0001)。
- 对照组D240两种抗体阳性率亦显著高于D210(p<0.05)。
- ARD组多因素logistic回归显示,高龄(OR=0.98,95%CI 0.96至1.0,p=0.024)、血管炎诊断(OR=0.24,95%CI 0.11至0.53,p<0.001)、泼尼松≥5 mg/天(OR=0.46,95%CI 0.27至0.77,p=0.003)、MMF(OR=0.30,95%CI 0.15至0.61,p<0.001)和生物制剂(OR=0.27,95%CI 0.16至0.46,p<0.001)与抗S1/S2 IgG阳性率降低相关。
- 泼尼松≥5 mg/天(OR=0.63,95%CI 0.44至0.90,p=0.011)、阿巴西普(OR=0.39,95%CI 0.20至0.74,p=0.004)、贝利尤单抗(OR=0.29,95%CI 0.13至0.67,p=0.004)和利妥昔单抗(OR=0.11,95%CI 0.04至0.30,p<0.001)与NAb阳性率降低相关。
- D210时COVID-19血清阴性的ARD患者D240抗S1/S2 IgG阳性率为80.5%,NAb阳性率为59.1%(p<0.0001)。
关键数值与推荐
- ARD患者D210抗S1/S2 IgG阳性率60%,D240为93%(p<0.0001);NAb阳性率D210为38%,D240为81.4%(p<0.0001)。
- D210血清阴性ARD患者D240抗S1/S2 IgG阳性率80.5%,NAb阳性率59.1%(p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the immunogenicity of the third dose of CoronaVac vaccine in a large population of patients with autoimmune rheumatic diseases (ARD) and the factors associated with impaired response. METHODS: Adult patients with ARD and age-balanced/sex-balanced controls (control group, CG) previously vaccinated with two doses of CoronaVac received the third dose at D210 (6 months after the second dose). The presence of anti-SARS-CoV-2 S1/S2 IgG and neutralising antibodies (NAb) was evaluated previously to vaccination (D210) and 30 days later (D240). Patients with controlled disease suspended mycophenolate mofetil (MMF) for 7 days or methotrexate (MTX) for 2 weekly doses after vaccination. RESULTS: ARD (n=597) and CG (n=199) had comparable age (p=0.943). Anti-S1/S2 IgG seropositivity rates significantly increased from D210 (60%) to D240 (93%) (p<0.0001) in patients with ARD. NAb positivity also increased: 38% (D210) vs 81.4% (D240) (p<0.0001). The same pattern was observed for CG, with significantly higher frequencies for both parameters at D240 (p<0.05). Multivariate logistic regression analyses in the ARD group revealed that older age (OR=0.98, 95% CI 0.96 to 1.0, p=0.024), vasculitis diagnosis (OR=0.24, 95% CI 0.11 to 0.53, p<0.001), prednisone ≥5 mg/day (OR=0.46, 95% CI 0.27 to 0.77, p=0.003), MMF (OR=0.30, 95% CI 0.15 to 0.61, p<0.001) and biologics (OR=0.27, 95% CI 0.16 to 0.46, p<0.001) were associated with reduced anti-S1/S2 IgG positivity. Similar analyses demonstrated that prednisone ≥5 mg/day (OR=0.63, 95% CI 0.44 to 0.90, p=0.011), abatacept (OR=0.39, 95% CI 0.20 to 0.74, p=0.004), belimumab (OR=0.29, 95% CI 0.13 to 0.67, p=0.004) and rituximab (OR=0.11, 95% CI 0.04 to 0.30, p<0.001) were negatively associated with NAb positivity. Further evaluation of COVID-19 seronegative ARD at D210 demonstrated prominent increases in positivity rates at D240 for anti-S1/S2 IgG (80.5%) and NAb (59.1%) (p<0.0001). CONCLUSIONS: We provide novel data on a robust response to the third dose of CoronaVac in patients with ARD, even in those with prevaccination COVID-19 seronegative status. Drugs implicated in reducing immunogenicity after the regular two-dose regimen were associated with non-responsiveness after the third dose, except for MTX. Trial registration number NCT04754698.
引用
- Aikawa NE, Kupa LVK, Medeiros-Ribeiro AC, et al. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Ann Rheum Dis. 2022. PMID: 35277389. doi:10.1136/annrheumdis-2021-222096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。